Cargando…

EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib

This report concerns a patient with skeletal muscle metastases due to lung adenocarcinoma harbouring an echinoderm microtubule-associated protein-like-4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement, who was successfully treated with lorlatinib after resistance to alectinib. A right lower lo...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuda, Hironari, Hara, Munechika, Iwakami, Shin-Ichiro, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088238/
https://www.ncbi.nlm.nih.gov/pubmed/33906872
http://dx.doi.org/10.1136/bcr-2020-240295
_version_ 1783686811924561920
author Matsuda, Hironari
Hara, Munechika
Iwakami, Shin-Ichiro
Takahashi, Kazuhisa
author_facet Matsuda, Hironari
Hara, Munechika
Iwakami, Shin-Ichiro
Takahashi, Kazuhisa
author_sort Matsuda, Hironari
collection PubMed
description This report concerns a patient with skeletal muscle metastases due to lung adenocarcinoma harbouring an echinoderm microtubule-associated protein-like-4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement, who was successfully treated with lorlatinib after resistance to alectinib. A right lower lobectomy based on a diagnosis of lung adenocarcinoma was performed on a 77-year-old Japanese woman. After 7 months of surgical resection, a mass in the right calf was observed. A fine-needle aspiration biopsy from the mass was performed and the mass was diagnosed as metastatic adenocarcinoma harbouring EML4-ALK rearrangement. Alectinib was administered for 10 months. Then, administration of lorlatinib, an ALK tyrosine kinase inhibitor classified as third generation, was initiated after resistance to treatment with alectinib. After starting treatment with lorlatinib, the gastrocnemius tumour diminished and has maintained a stable condition. Our case suggests that EML4-ALK positive lung adenocarcinoma is treatable with lorlatinib after resistance to treatment with alectinib.
format Online
Article
Text
id pubmed-8088238
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-80882382021-05-14 EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib Matsuda, Hironari Hara, Munechika Iwakami, Shin-Ichiro Takahashi, Kazuhisa BMJ Case Rep Case Report This report concerns a patient with skeletal muscle metastases due to lung adenocarcinoma harbouring an echinoderm microtubule-associated protein-like-4 (EML4)-anaplastic lymphoma kinase (ALK) rearrangement, who was successfully treated with lorlatinib after resistance to alectinib. A right lower lobectomy based on a diagnosis of lung adenocarcinoma was performed on a 77-year-old Japanese woman. After 7 months of surgical resection, a mass in the right calf was observed. A fine-needle aspiration biopsy from the mass was performed and the mass was diagnosed as metastatic adenocarcinoma harbouring EML4-ALK rearrangement. Alectinib was administered for 10 months. Then, administration of lorlatinib, an ALK tyrosine kinase inhibitor classified as third generation, was initiated after resistance to treatment with alectinib. After starting treatment with lorlatinib, the gastrocnemius tumour diminished and has maintained a stable condition. Our case suggests that EML4-ALK positive lung adenocarcinoma is treatable with lorlatinib after resistance to treatment with alectinib. BMJ Publishing Group 2021-04-27 /pmc/articles/PMC8088238/ /pubmed/33906872 http://dx.doi.org/10.1136/bcr-2020-240295 Text en © BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Case Report
Matsuda, Hironari
Hara, Munechika
Iwakami, Shin-Ichiro
Takahashi, Kazuhisa
EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
title EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
title_full EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
title_fullStr EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
title_full_unstemmed EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
title_short EML4-ALK positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
title_sort eml4-alk positive lung adenocarcinoma with skeletal muscle metastasis in the right calf which was treatable with lorlatinib after resistance to treatment with alectinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088238/
https://www.ncbi.nlm.nih.gov/pubmed/33906872
http://dx.doi.org/10.1136/bcr-2020-240295
work_keys_str_mv AT matsudahironari eml4alkpositivelungadenocarcinomawithskeletalmusclemetastasisintherightcalfwhichwastreatablewithlorlatinibafterresistancetotreatmentwithalectinib
AT haramunechika eml4alkpositivelungadenocarcinomawithskeletalmusclemetastasisintherightcalfwhichwastreatablewithlorlatinibafterresistancetotreatmentwithalectinib
AT iwakamishinichiro eml4alkpositivelungadenocarcinomawithskeletalmusclemetastasisintherightcalfwhichwastreatablewithlorlatinibafterresistancetotreatmentwithalectinib
AT takahashikazuhisa eml4alkpositivelungadenocarcinomawithskeletalmusclemetastasisintherightcalfwhichwastreatablewithlorlatinibafterresistancetotreatmentwithalectinib